StreetInsider.com News Articles

Form 144 Xenon Pharmaceuticals Filed by: KENNEY CHRISTOPHER JOHN

Fri, 28 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260828/26998393.html

Form 144 Xenon Pharmaceuticals Filed by: KENNEY CHRISTOPHER JOHN

Fri, 28 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260828/26998393.html

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:01:00 -0400

VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of August 27, 2026 and were granted as inducements material to the employees entering into

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:01:00 -0400

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:01:00 -0400

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 28 Aug 2026 16:01:00 -0400

Xenon to present phase 3 azetukalner data at European Epilepsy Congress

Wed, 26 Aug 2026 16:01:15 -0400

Xenon Pharmaceuticals Inc. (Nasdaq: XENE) plans to present six data sets at the 16th European Epilepsy Congress (EEC), scheduled for September 5-9, 2026, in Athens, Greece, according to a press release from the company.

The presentations include an oral session on topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), set for September 7. Two additional poster presentations will cover long-term seizure reduction, seizure freedom, and safety and tolerability data from patients who participated in the X-TOLE Open Label Extension (OLE) study for at least 48 months.

A separate poster will present mechanistic characterization of azetukalner, including KV7

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Wed, 26 Aug 2026 16:01:00 -0400

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results
New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs

VANCOUVER, BC and BOSTON, MA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced multiple data presentations at the upcoming 16^th European Epilepsy Congress (EEC), taking place September 5-9, 2026, in Athens, Greece.

Six presentations are

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Wed, 26 Aug 2026 16:01:00 -0400

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results
New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs

Six presentations are

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Wed, 26 Aug 2026 16:01:00 -0400

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results
New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs

Six presentations are

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Wed, 26 Aug 2026 16:01:00 -0400

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety results
New poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with commonly prescribed ASMs

Six presentations are

Form 4 Xenon Pharmaceuticals For: Aug 11 Filed by: GANNON STEVEN

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921973.html

Form 4 Xenon Pharmaceuticals For: Aug 11 Filed by: GANNON STEVEN

Thu, 13 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260813/26921973.html

Form 144 Xenon Pharmaceuticals Filed by: GANNON STEVEN

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921884.html

Form 144 Xenon Pharmaceuticals Filed by: GANNON STEVEN

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921884.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921012.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP

Thu, 13 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260813/26921012.html

H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)

Mon, 10 Aug 2026 06:41:55 -0400

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $74.00 price target on Xenon Pharmaceuticals (NASDAQ: XENE).

The analyst commented: "FDA raised no concerns around inadequate exposures at any dose during the pre-NDA meeting, and management believes the package supports approval of all four doses, with the 10 mg dose showing a placebo-like tolerability profile in a double-blind study. Roughly 60% of X-TOLE2 patients were either on cenobamate or had previously tried and discontinued it, and management indicated additional data on this subgroup may be published down the road, with peer-reviewed publication of the X-TOLE2 data an active priority alongside

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889269.html

Form SCHEDULE 13G/A Xenon Pharmaceuticals Filed by: FMR LLC

Fri, 07 Aug 2026 11:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26889269.html

Xenon Pharmaceuticals (XENE) PT Lowered to $81 at RBC Capital

Fri, 07 Aug 2026 07:33:33 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $81.00 (from $82.00) while maintaining a Outperform rating.

Form 10-Q Xenon Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884793.html

Form 10-Q Xenon Pharmaceuticals For: Jun 30

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884793.html

Xenon Pharmaceuticals (XENE) Tops Q2 EPS by 3c

Thu, 06 Aug 2026 16:22:53 -0400

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($1.11), $0.03 better than the analyst estimate of ($1.14).

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

Form 8-K Xenon Pharmaceuticals For: Aug 06

Thu, 06 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260806/26884079.html